Table 2.
Summary of the relationship between AGAP2-AS1 over-expressed and clinicopathological parameters.
| Heterogeneity | |||||||
| Clinicopathological parameters | Studies | Patients | OR (95% CI) | P-value | I 2 | P-value | Model |
| Age (older vs younger) | 8 | 797 | 0.78 (0.59, 1.05) | .10 | 46% | .07 | Fixed |
| Gender (male vs female) | 7 | 750 | 1.08 (0.80, 1.46) | .63 | 0% | .75 | Fixed |
| Tumor size (larger vs smaller) | 7 | 748 | 2.28 (1.24, 4.18) | .008 | 71% | .002 | Random |
| TNM stage (III + IV vs I + II) | 7 | 747 | 3.73 (2.71, 5.13) | <.00001 | 23% | .25 | Fixed |
| LNM (positive vs negative) | 4 | 404 | 2.95 (1.96, 4.45) | <.00001 | 12% | .33 | Fixed |
| DM (positive vs negative) | 2 | 162 | 1.83 (0.38, 8.69) | .45 | 71% | .06 | Random |
| Histological grade (well/moderately vs poorly) | 4 | 283 | 0.49 (0.11, 2.25) | .36 | 81% | .001 | Random |
AGAP2-AS1 = ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 antisense 1, CI = confidence interval, DM = distant metastasis, LNM = lymph node metastasis, OR = odds ratio.
Significance of bold values P <0.05.